Cargando…
A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients
BACKGROUND: Testosterone stimulates growth in many prostate tumours. The established GnRH analogue leuprolide acetate is incorporated in a novel biodegradable polymer matrix (Atrigel(® )delivery system), that can be administered to reduce testosterone levels in men with advanced hormone-dependent pr...
Autor principal: | Tunn, Ulf W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161957/ https://www.ncbi.nlm.nih.gov/pubmed/21801354 http://dx.doi.org/10.1186/1471-2490-11-15 |
Ejemplares similares
-
Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation
por: Tunn, Ulf W, et al.
Publicado: (2013) -
Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer
por: Spitz, A, et al.
Publicado: (2012) -
Leuprolide Acetate 1-Month Depot for Central Precocious Puberty: Hormonal Suppression and Recovery
por: Neely, E. Kirk, et al.
Publicado: (2010) -
Clinical development of the GnRH agonist leuprolide acetate depot
por: Chwalisz, Kristof
Publicado: (2022) -
Efficacy and Safety of Leuprolide Acetate 6-Month Depot for the Treatment of Central Precocious Puberty: A Phase 3 Study
por: Klein, Karen O, et al.
Publicado: (2023)